Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of X4 Pharmaceuticals, Inc (XFOR) since 2017 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of X4 Pharmaceuticals, Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1501697.
Total stock buying since 2017: $33,232,436.
Total stock sales since 2017: $2,585,307.
Total stock option exercises since 2017: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 1,032 | $2,561 | 214,287 | $97,295 | 0 | $0 |
| 2024 | 0 | $0 | 877,967 | $549,423 | 0 | $0 |
| 2023 | 25,000 | $29,875 | 999,042 | $890,155 | 0 | $0 |
| 2022 | 0 | $0 | 100,859 | $7,613 | 0 | $0 |
| 2021 | 0 | $0 | 72,050 | $443,269 | 0 | $0 |
| 2020 | 0 | $0 | 73,549 | $597,552 | 0 | $0 |
| 2017 | 3,320,000 | $33,200,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-05 | 1,032 | $2,561 | 0 | $0 | 0 | $0 |
| 2025-01 | 0 | $0 | 214,287 | $97,295 | 0 | $0 |
| 2024-11 | 0 | $0 | 31,897 | $12,599 | 0 | $0 |
| 2024-10 | 0 | $0 | 657,720 | $364,359 | 0 | $0 |
| 2024-09 | 0 | $0 | 2,642 | $1,738 | 0 | $0 |
| 2024-03 | 0 | $0 | 131,822 | $116,367 | 0 | $0 |
| 2024-02 | 0 | $0 | 53,886 | $54,360 | 0 | $0 |
| 2023-11 | 0 | $0 | 615,729 | $456,263 | 0 | $0 |
| 2023-08 | 25,000 | $29,875 | 130,056 | $137,859 | 0 | $0 |
| 2023-06 | 0 | $0 | 55,097 | $117,675 | 0 | $0 |
| 2023-05 | 0 | $0 | 6,292 | $12,269 | 0 | $0 |
| 2023-03 | 0 | $0 | 137,176 | $115,227 | 0 | $0 |
| 2023-02 | 0 | $0 | 54,692 | $50,862 | 0 | $0 |
| 2022-08 | 0 | $0 | 34,329 | $0 | 0 | $0 |
| 2022-06 | 0 | $0 | 44,835 | $7,613 | 0 | $0 |
| 2022-02 | 0 | $0 | 21,695 | $0 | 0 | $0 |
| 2021-08 | 0 | $0 | 32,612 | $166,320 | 0 | $0 |
| 2021-07 | 0 | $0 | 13,448 | $77,729 | 0 | $0 |
| 2021-06 | 0 | $0 | 18,790 | $140,132 | 0 | $0 |
| 2021-03 | 0 | $0 | 2,400 | $23,376 | 0 | $0 |
| 2021-02 | 0 | $0 | 2,400 | $18,912 | 0 | $0 |
| 2021-01 | 0 | $0 | 2,400 | $16,800 | 0 | $0 |
| 2020-12 | 0 | $0 | 4,800 | $33,600 | 0 | $0 |
| 2020-10 | 0 | $0 | 2,400 | $16,800 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-05-16 | Baldry Mark (Chief Commercial Officer) | Buy | 1,032 | 2.48 | 2,561 |
| 2025-01-24 | Dibiase Mary (Chief Operating Officer) | Sale | 22,258 | .45 | 10,105 |
| 2025-01-24 | Arbet-engels Christophe (Chief Medical Officer) | Sale | 11,624 | .46 | 5,288 |
| 2025-01-24 | Ragan Paula (President and CEO) | Sale | 76,473 | .45 | 34,718 |
| 2025-01-24 | Mostafa Adam S. (Chief Financial Officer) | Sale | 74,773 | .45 | 33,946 |
| 2025-01-24 | Baldry Mark (Chief Commercial Officer) | Sale | 29,159 | .45 | 13,238 |
| 2024-11-15 | Ragan Paula (President and CEO) | Sale | 31,897 | .40 | 12,599 |
| 2024-10-15 | Ragan Paula (President and CEO) | Sale | 31,897 | .56 | 17,926 |
| 2024-10-07 | Dibiase Mary (Chief Operating Officer) | Sale | 67,695 | .57 | 38,315 |
| 2024-10-07 | Taveras Arthur (Chief Scientific Officer) | Sale | 76,920 | .56 | 43,305 |
| 2024-10-07 | Ragan Paula (President and CEO) | Sale | 239,436 | .55 | 131,450 |
| 2024-10-07 | Mostafa Adam S. (Chief Financial Officer) | Sale | 230,645 | .55 | 126,854 |
| 2024-10-07 | Baldry Mark (Chief Commercial Officer) | Sale | 11,127 | .58 | 6,509 |
| 2024-09-09 | Dibiase Mary (Chief Operating Officer) | Sale | 2,642 | .66 | 1,738 |
| 2024-03-11 | Dibiase Mary (Chief Operating Officer) | Sale | 15,409 | .88 | 13,590 |
| 2024-03-11 | Taveras Arthur (Chief Scientific Officer) | Sale | 14,235 | .88 | 12,555 |
| 2024-03-11 | Ragan Paula (President and CEO) | Sale | 49,678 | .88 | 43,865 |
| 2024-03-11 | Mostafa Adam S. (Chief Financial Officer) | Sale | 52,500 | .88 | 46,357 |
| 2024-02-12 | Dibiase Mary (Chief Operating Officer) | Sale | 3,683 | 1.01 | 3,708 |
| 2024-02-12 | Taveras Arthur (Chief Scientific Officer) | Sale | 787 | 1.01 | 792 |
| 2024-02-12 | Ragan Paula (President and CEO) | Sale | 21,695 | 1.01 | 21,890 |
| 2024-02-12 | Mostafa Adam S. (Chief Financial Officer) | Sale | 27,721 | 1.01 | 27,970 |
| 2023-11-03 | Ragan Paula (President and CEO) | Sale | 39,906 | .90 | 35,915 |
| 2023-11-01 | Dibiase Mary (Chief Operating Officer) | Sale | 67,695 | .73 | 49,417 |
| 2023-11-01 | Taveras Arthur (Chief Scientific Officer) | Sale | 67,695 | .73 | 49,417 |
| 2023-11-01 | Ragan Paula (President and CEO) | Sale | 199,531 | .73 | 145,657 |
| 2023-11-01 | Mostafa Adam S. (Chief Financial Officer) | Sale | 230,645 | .73 | 168,370 |
| 2023-11-01 | Baldry Mark (Chief Commercial Officer) | Sale | 10,257 | .73 | 7,487 |
| 2023-08-18 | Wyzga Michael S (Director) | Buy | 25,000 | 1.20 | 29,875 |
| 2023-08-10 | Stewart Murray (Interim Chief Medical Officer) | Sale | 130,056 | 1.06 | 137,859 |
| 2023-06-30 | Dibiase Mary (Chief Operating Officer) | Sale | 464 | 1.89 | 876 |
| 2023-06-30 | Mostafa Adam S. (Chief Financial Officer) | Sale | 2,641 | 1.89 | 4,991 |
| 2023-06-23 | Dibiase Mary (Chief Operating Officer) | Sale | 857 | 1.93 | 1,654 |
| 2023-06-23 | Ragan Paula (President and CEO) | Sale | 6,724 | 1.92 | 12,910 |
| 2023-06-23 | Mostafa Adam S. (Chief Financial Officer) | Sale | 5,417 | 1.93 | 10,454 |
| 2023-06-15 | Dibiase Mary (Chief Operating Officer) | Sale | 1,714 | 2.23 | 3,822 |
| 2023-06-15 | Ragan Paula (President and CEO) | Sale | 13,448 | 2.23 | 29,988 |
| 2023-06-15 | Mostafa Adam S. (Chief Financial Officer) | Sale | 10,834 | 2.22 | 24,050 |
| 2023-05-31 | Ragan Paula (President and CEO) | Sale | 6,292 | 1.95 | 12,269 |
| 2023-03-10 | Dibiase Mary (Chief Operating Officer) | Sale | 18,192 | .84 | 15,281 |
| 2023-03-10 | Taveras Arthur (Chief Scientific Officer) | Sale | 16,806 | .84 | 14,117 |
| 2023-03-10 | Ragan Paula (President and CEO) | Sale | 49,678 | .84 | 41,729 |
| 2023-03-10 | Mostafa Adam S. (Chief Financial Officer) | Sale | 52,500 | .84 | 44,100 |
| 2023-02-13 | Dibiase Mary (Chief Operating Officer) | Sale | 4,348 | .93 | 4,043 |
| 2023-02-13 | Taveras Arthur (Chief Scientific Officer) | Sale | 928 | .93 | 863 |
| 2023-02-13 | Ragan Paula (President and CEO) | Sale | 21,695 | .93 | 20,176 |
| 2023-02-13 | Mostafa Adam S. (Chief Financial Officer) | Sale | 27,721 | .93 | 25,780 |
| 2022-08-17 | Dibiase Mary (Chief Operating Officer) | Sale | 1,713 | .00 | 0 |
| 2022-08-17 | Ragan Paula (President and CEO) | Sale | 13,448 | .00 | 0 |
| 2022-08-17 | Meisner Derek M (Chief Legal Officer) | Sale | 8,334 | .00 | 0 |
| 2022-08-17 | Mostafa Adam S. (Chief Financial Officer) | Sale | 10,834 | .00 | 0 |
| 2022-06-30 | Dibiase Mary (Chief Operating Officer) | Sale | 1,578 | .00 | 0 |
| 2022-06-30 | Mostafa Adam S. (Chief Financial Officer) | Sale | 2,641 | .00 | 0 |
| 2022-06-24 | Dibiase Mary (Chief Operating Officer) | Sale | 856 | .00 | 0 |
| 2022-06-24 | Ragan Paula (President and CEO) | Sale | 6,724 | .00 | 0 |
| 2022-06-24 | Meisner Derek M (Chief Legal Officer) | Sale | 4,166 | .00 | 0 |
| 2022-06-24 | Mostafa Adam S. (Chief Financial Officer) | Sale | 5,416 | .00 | 0 |
| 2022-06-16 | Dibiase Mary (Chief Operating Officer) | Sale | 856 | .00 | 0 |
| 2022-06-16 | Ragan Paula (President and CEO) | Sale | 6,724 | .00 | 0 |
| 2022-06-16 | Meisner Derek M (Chief Legal Officer) | Sale | 4,166 | .00 | 0 |
| 2022-06-16 | Mostafa Adam S. (Chief Financial Officer) | Sale | 5,416 | .00 | 0 |
| 2022-06-03 | Ragan Paula (President and CEO) | Sale | 6,292 | 1.21 | 7,613 |
| 2022-02-11 | Ragan Paula (President and CEO) | Sale | 21,695 | .00 | 0 |
| 2021-08-17 | Ragan Paula (President and CEO) | Sale | 13,448 | 5.10 | 68,584 |
| 2021-08-17 | Meisner Derek M (General Counsel) | Sale | 8,332 | 5.10 | 42,493 |
| 2021-08-17 | Mostafa Adam S. (Chief Financial Officer) | Sale | 10,832 | 5.10 | 55,243 |
| 2021-07-15 | Ragan Paula (President and CEO) | Sale | 13,448 | 5.78 | 77,729 |
| 2021-06-30 | Mostafa Adam S. (Chief Financial Officer) | Sale | 2,641 | 6.64 | 17,536 |
| 2021-06-24 | Meisner Derek M (General Counsel) | Sale | 4,166 | 7.00 | 29,162 |
| 2021-06-24 | Mostafa Adam S. (Chief Financial Officer) | Sale | 5,417 | 7.01 | 37,973 |
| 2021-06-15 | Meisner Derek M (General Counsel) | Sale | 4,166 | 7.84 | 32,661 |
| 2021-06-02 | Ragan Paula (President and CEO) | Sale | 2,400 | 9.50 | 22,800 |
| 2021-03-02 | Ragan Paula (President and CEO) | Sale | 2,400 | 9.74 | 23,376 |
| 2021-02-02 | Ragan Paula (President and CEO) | Sale | 2,400 | 7.88 | 18,912 |
| 2021-01-05 | Ragan Paula (President and CEO) | Sale | 2,400 | 7.00 | 16,800 |
| 2020-12-23 | Ragan Paula (President and CEO) | Sale | 4,800 | 7.00 | 33,600 |
| 2020-10-05 | Ragan Paula (President and CEO) | Sale | 1,797 | 7.00 | 12,579 |
| 2020-10-02 | Ragan Paula (President and CEO) | Sale | 603 | 7.00 | 4,221 |
| 2020-09-21 | Mostafa Adam S. (Chief Financial Officer) | Sale | 10,834 | 7.08 | 76,704 |
| 2020-09-09 | Skerlj Renato (Chief Scientific Officer) | Sale | 5,834 | 8.05 | 46,963 |
| 2020-09-09 | Ragan Paula (President and CEO) | Sale | 8,840 | 8.04 | 71,073 |
| 2020-09-09 | Meisner Derek M (General Counsel) | Sale | 8,334 | 8.05 | 67,088 |
| 2020-09-02 | Ragan Paula (President and CEO) | Sale | 2,400 | 7.99 | 19,176 |
| 2020-08-03 | Ragan Paula (President and CEO) | Sale | 2,400 | 7.45 | 17,880 |
| 2020-07-02 | Ragan Paula (President and CEO) | Sale | 2,400 | 9.05 | 21,720 |
| 2020-06-30 | Mostafa Adam S. (See Remarks) | Sale | 1,725 | 9.04 | 15,593 |
| 2020-06-03 | Ragan Paula (President and CEO) | Sale | 9,707 | 8.88 | 86,198 |
| 2020-06-02 | Ragan Paula (President and CEO) | Sale | 2,400 | 8.65 | 20,760 |
| 2020-06-01 | Ragan Paula (President and CEO) | Sale | 4,275 | 8.63 | 36,893 |
| 2020-05-04 | Ragan Paula (President and CEO) | Sale | 2,400 | 8.92 | 21,408 |
| 2020-04-02 | Ragan Paula (President and CEO) | Sale | 2,400 | 8.40 | 20,160 |
| 2020-03-02 | Ragan Paula (President and CEO) | Sale | 2,400 | 10.64 | 25,536 |
| 2017-11-20 | Neomed Innovation V Ltd (10% Owner) | Buy | 300,000 | 10.00 | 3,000,000 |
| 2017-11-20 | Gerngross Tillman U. (Director) | Buy | 200,000 | 10.00 | 2,000,000 |
| 2017-11-20 | Nessi Claudio (Director) | Buy | 300,000 | 10.00 | 3,000,000 |
| 2017-11-20 | Muhlenbeck Frank (10% Owner) | Buy | 20,000 | 10.00 | 200,000 |
| 2017-11-20 | Sv Life Sciences Fund V Lp (10% Owner) | Buy | 500,000 | 10.00 | 5,000,000 |
| 2017-11-20 | Flint Jonathan A (10% Owner) | Buy | 500,000 | 10.00 | 5,000,000 |
| 2017-11-20 | Gordon Carl L (Director) | Buy | 500,000 | 10.00 | 5,000,000 |
| 2017-11-20 | Ross Michael Jay (Director) | Buy | 500,000 | 10.00 | 5,000,000 |
| 2017-11-20 | Mcguire Terrance (Director) | Buy | 500,000 | 10.00 | 5,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of XFOR listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of X4 Pharmaceuticals, Inc (symbol XFOR, CIK number 1501697) see the Securities and Exchange Commission (SEC) website.